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Controls Growth in Its Open State,
and Phosphorylation Converts It
to a Less-Active More-Closed StateThe neurofibromatosis type 2 (NF2) tumor
suppressor merlin plays an important role
in contact inhibition of cell growth. It
shows high similarity to the ezrin-radixin-
moesin (ERM) proteins with which it
shares three distinct structural domains:
a highly conserved N-terminal four-
point-one ERM (FERM) domain (residues
1–335), an a-helical domain (residues
336–505), and a C-terminal tail domain
(CTT, residues 506–595) that can asso-
ciate with the FERM domain to modulate
the accessibility to its ligands, which
include the scaffolding protein EBP50
(reviewed in Fehon et al., 2010). ERMs
are activated in part by phosphorylation
of a conserved threonine in the CTT that
reduces the FERM/CTT association to
convert the protein from a closed to a
more open active state. Similar to ERMs,
merlin is regulated by phosphorylation
on a unique CTT residue (Ser518) (re-
viewed in Bretscher et al., 2002). Limited
evidence suggests that, similar to ERMs,
phosphorylation of Ser518 reduces the
FERM/CTT association (Rong et al.,
2004; Shaw et al., 2001). However, in
contrast to the ERMs, studies consis-
tently show that this phosphorylation
event leads to deactivation of merlin
(Shaw et al., 2001; Surace et al., 2004),
and a binary switch model has emerged,
showing that nonphosphorylated closed
merlin represents the active state and
that phosphorylation opens the molecule
to inactivate it. This model presents
a paradox, because, for example, the
interaction of merlin with growth factor
receptors through EBP50 is required for
growth regulation (Curto et al., 2007;
James et al., 2004) yet would not be ex-
pected to occur with closed merlin.
We set out to rigorously test the current
model by characterizing a spectrum of
merlin variants with different degrees of
association of the CTT with the FERM
domain. Because the merlin FERM/CTT
interaction is not as strong as in ezrin
(Nguyen et al., 2001), we engineered(based on similarities in the CTT of merlin
and EBP50; see Figures S1A and S1B
available online) a merlin mutant (desig-
nated ‘‘AR’’) with a more stable closed
form. As strongly open controls, we
used a mutant missing the last two
residues (DEL) and the splice variant iso-
form 2 (M2) with altered CTT (Nguyen
et al., 2001). We compared these with
wild-type (WT) merlin, the phosphodefi-
cient S518A mutant, the phosphomimetic
S518D (Shaw et al., 2001) and S518E
mutants, and a merlin fragment genuinely
phosphorylated on Ser518.
First we compared the interaction of the
variant Cter fragments (residues 342–end)
with the Nter (residues 1–341) in vitro. As
predicted, the AR Cter bound Nter most
effectively (Figures 1A and 1B). Surpris-
ingly, and in contrast to earlier findings,
S518A Cter showed reduced Nter
binding, whereas Cter containing S518D
or S518E mutations exhibited increased
binding. Similar results were obtained
with shorter fragments containing only
the CTT and FERM domains (Figures
S1C and S1D) and when the Cter frag-
ments were used to recover Nter ex-
pressed in cells (Figure S1E). Moreover,
when these fragments were coexpressed
in 293T cells, Cter containing S518D and
AR mutations efficiently recovered the
Nter, but WT, S518A, M2, and DEL
constructs recovered little or none
(Figure 1C). To directly determine the
effect of S518 phosphorylation on the
Nter/Cter interaction, WT Cter was phos-
phorylated in vitro. Phosphorylation
(30% yield) resulted in an ATP-depen-
dent shifted band specifically recognized
by an S518-phosphomerlin antibody and
not seen with S518A (Figure 1D). Immobi-
lized Nter bound the phosphorylated Cter
about 10-fold more effectively, binding
about 11% of the input compared to
1% for the unphosphorylated species
(Figure 1E), directly demonstrating that
phosphorylation of S518 enhances the
FERM/CTT interaction.Developmental CelBecause the binding site for EBP50 on
the FERM domain is masked by bound
CTT (Bretscher et al., 2002), the accessi-
bility of this site reflects full-length
merlin’s conformation. Full-length AR
mutant expressed in 293T cells fails to
bind immobilized EBP50 and is therefore
highly closed, whereas DEL bound as
effectively as the free FERM domain. WT
(which is subject to phosphorylation
in vivo) and S518D bound poorly, whereas
S518A bound more efficiently (Figure 1F).
Similar results were obtainedwith bacteri-
ally purified proteins (Figure S1F). Taken
together, our resultsdocument ahierarchy
of closure, with the AR mutant the most
tightly closed, followed by S518D, which
is more closed than unmodified WT,
then S518A, and finally M2 and DEL,
which are fully open.
We assessed the ability of these
mutants to control cell growth, using the
nonfunctional L64P mutant (Gutmann
et al., 1998) as a control. All constructs,
except mutant L64P, localized mostly to
the plasma membrane, indicating that
both open and closed conformations of
merlin associate with the plasma mem-
brane (data not shown). Mutant L64P
and the more closed mutants AR and
S518D failed to block the proliferation of
merlin-deficient human schwannoma
cells, whereas WT merlin and the more
open S518A and M2 were proficient at
growth control, even though their expres-
sion levels were significantly lower
compared to the closed mutants (Figures
1G and 1H). Consistent results were ob-
tained with mouse 3T3 cells and primary
human schwannoma cells. In all cases,
a more open conformation correlates
with higher growth control activity and
enhances association with growth
factor receptors through EBP50 (Figures
S1G–S1J).
In accord with the rheostat model of
conformational regulation suggested for
ERM proteins (Li et al., 2007), these
results show that WT merlin tends not
to be fully open or closed, but rather
varies in its degree of openness depend-
ing on its circumstances. In contrast to
previous work (Shaw et al., 2001; Surace
et al., 2004), our studies support a model
in which the conformationally open state
of merlin is the one that favors growth
control, with S518 phosphorylation being
a central regulatory event enhancing the
FERM/CTT association, tipping thel 22, April 17, 2012 ª2012 Elsevier Inc. 703
Figure 1. Biochemical Properties and Growth Suppression of Merlin Variants
(A) GST-Cter fragments bound to glutathione-sepharose beads were used to recover untagged Nter expressed in bacteria.
(B) Quantification of Nter binding (mean ± SD).
(C) 293T cells expressing HA-Nter and either vector (V) or Myc-tagged Cter (Myc-Cter). Myc immunoprecipitates were immunoblotted as indicated.
(D) Untagged Cter incubated with p21 activated kinase (PAK2) in the presence (+) or absence () of ATP, resolved on 15% SDS-PAGE gel and immunoblotted
with anti-phospho-merlin (p-S518) (red) and anti-merlin (green) (top) or total merlin (bottom).
(E) Immobilized Nter was used to recover phosphorylated WT Cter or mutated Cter fragments.
(F) Relative binding by GST-EBP50 to full-length mutants expressed in 293T cells (mean ± SD).
(G) Merlin levels in HEI-193 cells stably expressing merlin variants.
(H) HEI-193 cells were serum starved, restimulated with serum, and examined for relative BrdU incorporation (mean ± SD).
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Correspondencebalance toward a more (but not fully)
closed molecule with reduced ability to
control cell growth. Unmodified merlin
(like S518A) is in a more open state and
is therefore more active in growth
control. Because the amount of active
merlin necessary for growth control may
vary between different experimental
settings, it is not surprising to see the
apparently variable results found in the704 Developmental Cell 22, April 17, 2012 ª2field. That S518A is not as open as M2
or DEL and S518D is not as closed as
AR implies that additional factors can
further regulate the balance between
open and closed states. With this new
model in hand, and the AR and DEL
mutants available as tightly closed and
open forms of merlin, the stage is set
for studies to identify and characterize
in detail the effectors that selectively012 Elsevier Inc.associate with merlin in its different
conformations and how these impinge
on the regulation of cell growth and other
merlin functions.
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